ASP Isotopes (NASDAQ:ASPI) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of ASP Isotopes (NASDAQ:ASPI) from a strong sell rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $13.00.

ASP Isotopes Price Performance

Shares of ASP Isotopes stock opened at $4.00 on Friday. The stock has a 50 day moving average of $4.94 and a 200 day moving average of $5.32. ASP Isotopes has a 12 month low of $3.51 and a 12 month high of $14.49. The firm has a market cap of $613.24 million, a PE ratio of -3.03 and a beta of 3.61. The company has a current ratio of 3.87, a quick ratio of 4.37 and a debt-to-equity ratio of 0.76.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11). ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%. The firm had revenue of $5.12 million for the quarter, compared to analysts’ expectations of $4.47 million.

Insider Activity

In related news, Director Todd Wider sold 50,000 shares of ASP Isotopes stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $6.25, for a total value of $312,500.00. Following the completion of the transaction, the director owned 722,247 shares in the company, valued at approximately $4,514,043.75. This trade represents a 6.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Paul Elliot Mann sold 83,759 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $7.76, for a total value of $649,969.84. Following the sale, the chief executive officer directly owned 9,579,845 shares in the company, valued at $74,339,597.20. The trade was a 0.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 279,079 shares of company stock worth $2,049,208. 14.40% of the stock is owned by insiders.

Institutional Investors Weigh In On ASP Isotopes

Institutional investors have recently modified their holdings of the stock. State of Wyoming bought a new position in shares of ASP Isotopes during the 1st quarter valued at approximately $29,000. Quantbot Technologies LP bought a new stake in ASP Isotopes in the third quarter worth $34,000. BNP Paribas Financial Markets lifted its position in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares during the last quarter. Stephens Inc. AR bought a new stake in ASP Isotopes in the first quarter worth $44,000. Finally, Broadhurst Jeffrey B purchased a new position in ASP Isotopes during the first quarter worth $44,000. 16.80% of the stock is owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.